Trials / Completed
CompletedNCT00715702
Safety Study of AZD5672 in Renally Impaired Subjects
An Open-Label, Single-Centre, Parallel Group, Phase I Study To Compare the Pharmacokinetics of AZD5672 Single Dose in Patients With Renal Impairment and Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to investigate the pharmacokinetics of a single dose of AZD5672 in patients with renal impairment by comparing with healthy volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD5672 | 100 mg oral single dose |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-07-15
- Last updated
- 2009-04-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00715702. Inclusion in this directory is not an endorsement.